Alto Neuroscience (NYSE:ANRO) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Other equities research analysts have also recently issued research reports about the stock. Wedbush lifted their price target on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. BTIG Research increased their price objective on shares of Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alto Neuroscience in a report on Wednesday, July 29th. Finally, Robert W. Baird dropped their target price on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $32.01 on Friday. The business’s 50-day simple moving average is $30.68 and its 200 day simple moving average is $25.33. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -13.23 and a beta of 1.13. Alto Neuroscience has a 12-month low of $3.59 and a 12-month high of $37.48. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. As a group, research analysts anticipate that Alto Neuroscience will post -2.68 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. acquired a new position in Alto Neuroscience during the first quarter valued at approximately $67,000. AQR Capital Management LLC acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $52,000. Marshall Wace LLP raised its holdings in Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after buying an additional 84,417 shares during the period. Jane Street Group LLC acquired a new position in shares of Alto Neuroscience in the second quarter valued at approximately $240,000. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Alto Neuroscience by 85.9% in the second quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after buying an additional 25,000 shares during the period.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.